| Du, Juan |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old. |
|
|
| Recruiting | 2 | 420 | RoW | 2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC | Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital | Tuberculosis | 05/24 | 06/24 | | |
PAAG, NCT05493995: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. |
|
|
| Completed | 2 | 66 | RoW | Penpulimab, AK105, Anlotinib, Nab paclitaxel, Gemcitabine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pancreatic Neoplasms | 05/24 | 05/24 | | |
NCT05594797: Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM |
|
|
| Recruiting | 2 | 100 | RoW | Human BCMA Targeted T Cells Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital, First Affiliated Hospital of Wenzhou Medical University | Multiple Myeloma | 07/25 | 07/27 | | |
| Recruiting | 1/2 | 20 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 07/23 | 07/23 | | |
NCT05302648: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM |
|
|
| Active, not recruiting | 1 | 18 | RoW | Human Derived anti-BCMA CAR-T Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05412329: Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 9 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT06407947: Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | Chimeric antigen receptor modified T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma | 06/27 | 06/27 | | |
| Active, not recruiting | 1 | 20 | RoW | Experimental: CAR-T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma, Primary Plasma Cell Leukemia | 07/25 | 07/25 | | |
NCT06718270: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia |
|
|
| Recruiting | 1 | 24 | RoW | CAR-T cells Infusion | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 01/27 | 12/27 | | |
NCT05840107: Study of FasT CAR-T GC012F Injection NDMM Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 09/25 | 09/25 | | |
NCT06045091: To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL |
|
|
| Recruiting | 1 | 18 | RoW | Human BCMA targeted CAR-NK cells injection, BCMA CAR-NK | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma, Plasma Cell Leukemia | 09/25 | 09/27 | | |
| Zhang, Wenhong |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT04201808: Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides |
|
|
| Recruiting | 4 | 100 | RoW | Tenofovir Alafenamide 25 MG, Vemlidy | New Discovery LLC, Beijing Ditan Hospital | Hepatitis B, Chronic | 09/23 | 09/23 | | |
NCT05279235: Efficacy and Safety of JT001 (VV116) Compared With Favipiravir |
|
|
| Terminated | 3 | 290 | RoW | JT001, VV116, JT001 placebo, VV116 placebo, Favipiravir, Favipiravir placebo | Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH | Moderate to Severe COVID-19 | 12/22 | 12/22 | | |
| Recruiting | 3 | 360 | RoW | ZX-7101A, Placebo | Nanjing Zenshine Pharmaceuticals | Respiratory Viral Infection | 01/25 | 03/25 | | |
NCT05242042: JT001 (VV116) for the Early Treatment of COVID-19 |
|
|
| Terminated | 2/3 | 381 | RoW | JT001, VV116, Placebo | Shanghai JunTop Biosciences Co., LTD, Sponsor GmbH | Mild to Moderate COVID-19 | 03/23 | 03/23 | | |
NCT05445934: Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study) |
|
|
| Recruiting | 2/3 | 1188 | RoW | FB2001, DC402234, FB2001 placebo | Frontier Biotechnologies Inc. | COVID-19 | 11/23 | 12/23 | | |
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) |
|
|
| Recruiting | 2 | 280 | Europe, Canada, Japan, US, RoW | Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo | GlaxoSmithKline | Chronic Hepatitis B Virus Infection, Hepatitis B | 10/27 | 10/27 | | |
NCT05217732: Study to Assess the Safety, Tolerability and Pharmacokinetics of ZX-7101A and the Food Effect in Healthy Volunteers |
|
|
| Completed | 1 | 66 | RoW | ZX-7101A, Placebo | Nanjing Zenshine Pharmaceuticals | Safety Issues, Tolerance, Pharmacokinetics, Food Effect | 08/22 | 12/22 | | |
| Pei, Yi |
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
|
|
| Not yet recruiting | 1 | 72 | RoW | Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT) | Healthgen Biotechnology Corp. | Pleurisy | 07/25 | 12/25 | | |
